TrialThe Lancet. Respiratory medicine2022

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.

Jing-Xin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.